Literature DB >> 3560398

Cholesterol and mortality. 30 years of follow-up from the Framingham study.

K M Anderson, W P Castelli, D Levy.   

Abstract

From 1951 to 1955 serum cholesterol levels were measured in 1959 men and 2415 women aged between 31 and 65 years who were free of cardiovascular disease (CVD) and cancer. Under age 50 years, cholesterol levels are directly related with 30-year overall and CVD mortality; overall death increases 5% and CVD death 9% for each 10 mg/dL. After age 50 years there is no increased overall mortality with either high or low serum cholesterol levels. There is a direct association between falling cholesterol levels over the first 14 years and mortality over the following 18 years (11% overall and 14% CVD death rate increase per 1 mg/dL per year drop in cholesterol levels). Under age 50 years these data suggest that having a very low cholesterol level improves longevity. After age 50 years the association of mortality with cholesterol values is confounded by people whose cholesterol levels are falling--perhaps due to diseases predisposing to death.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3560398     DOI: 10.1001/jama.257.16.2176

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  171 in total

Review 1.  Impact of dyslipidaemia. Lessons from clinical trials.

Authors:  W V Brown
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 2.  Resource utilisation in the management of dyslipidaemia.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

3.  Risk factor thresholds. Threshold is 37 000 pounds sterling per QALY.

Authors:  Michael A Soljak
Journal:  BMJ       Date:  2002-11-09

Review 4.  Implications of the heart protection study for reducing coronary events in high-risk patients.

Authors:  William Virgil Brown; Warren Davis; Matthey Harris
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

5.  Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio.

Authors:  Peter Blaha; Ruth Exner; Andrea Dal Borgo; Sinda Bigenzahn; Peter Panhofer; Otto Riedl; Sebastian Schoppmann; Thomas Bachleitner-Hofmann; Emanuel Sporn; Ursula Pluschnig; Florian Fitzal; Guenther Steger; Raimund Jakesz; Peter Dubsky; Michael Gnant
Journal:  Breast Care (Basel)       Date:  2009-06-23       Impact factor: 2.860

6.  Cohort studies: history of the method. I. Prospective cohort studies.

Authors:  R Doll
Journal:  Soz Praventivmed       Date:  2001

Review 7.  Statin therapy in the elderly: does it make good clinical and economic sense?

Authors:  Moira M B Mungall; Allan Gaw; James Shepherd
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis.

Authors:  C K Hui; B M Y Cheung; G K K Lau
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

9.  Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.

Authors:  Tomoyuki Nishimoto; Yuichiro Amano; Ryuichi Tozawa; Eiichiro Ishikawa; Yoshimi Imura; Hidefumi Yukimasa; Yasuo Sugiyama
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

10.  Gender differences in acculturation, stress, and salivary cortisol response among former Soviet immigrants.

Authors:  Lisa M Nicholson; Arlene Michaels Miller; Dorie Schwertz; Olga Sorokin
Journal:  J Immigr Minor Health       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.